The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate MergerHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate MergerShanthi RexalineBenzingaJanuary 3, 2020ReblogShareTweetShareHere's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech stocks hitting 52-week highs on Jan. 2)Agile Therapeutics Inc (NASDAQ: AGRX (announced the appointment of healthcare industry veteran Kimberly Whelan as VP, Market Access, as it prepares for a potential Twirla commercial launch)Aimmune Therapeutics Inc (NASDAQ: AIMT)Applied Therapeutics Inc (NASDAQ: APLT)Ascendis Pharma A/S (NASDAQ: ASND)Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV)Cassava Sciences Inc (NASDAQ: SAVA)ChemoCentryx Inc (NASDAQ: CCXI)DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT)Epizyme Inc (NASDAQ: EPZM)Esperion Therapeutics Inc (NASDAQ: ESPR)Fortress Biotech (NASDAQ: FBIO)INNATE PHARMA S/S ADR (NASDAQ: IPHA)(announced EMA acceptance of regulatory application for drug to treat hairy cell leukemia)The Medicines Company (NASDAQ: MDCO)Mesoblast limited (NASDAQ: MESO)(announced submission of safety and efficacy data as part of rolling BLA submission for remestemcell-L for the treatment of children with steroid-refractory acute graft versus host disease)Mirati Therapeutics Inc (NASDAQ: MRTX)Nevro Corp (NYSE: NVRO)NuVasive, Inc. (NASDAQ: NUVA)Otonomy Inc (NASDAQ: OTIC)Syneos Health Inc (NASDAQ: SYNH)Urovant Sciences Ltd (NASDAQ: UROV)Veru Inc (NASDAQ: VERU)West Pharmaceutical Services Inc. (NYSE: WST)Zoetis Inc (NYSE: ZTS)Down In The Dumps(Biotech stocks hitting 52-week lows on Jan. 2)Alterity Therapeutics Ltd (NASDAQ: ATHE)Evelo Biosciences Inc (NASDAQ: EVLO)Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)Stealth BioTherapeutics Corp (NASDAQ: MITO)Wave Life Sciences Ltd (NASDAQ: WVE)Xeris Pharmaceuticals Inc (NASDAQ: XERS)Stocks In Focus Acorda Gains After Hedge Fund Hikes StakeAcorda Therapeutics Inc (NASDAQ: ACOR) shares gained after hedge fund Point72 Asset Management led by Steven Cohen raised its stake in the company to 9.8%.The stock gained 20.41% to $2.36 in after-hours trading.Incyte's Graft-Versus-Host Disease Drug Fails to Meet Primary & Key Secondary Endpoints In Late-stage StudyIncyte Corporation (NASDAQ: INCY) said a Phase 3 study dubbed GRAVITAS-301 that evaluated its itacitinib in combination with corticosteroids in patients with treatment-naïve graft-versus-host disease did not meet the primary endpoint of improving overall response rate at Day 28 compared to placebo plus corticosteroids.The study also did not meet the key secondary endpoint, with no difference shown in non-relapse mortality at Week 6, the company added.The stock slipped 10.08% to $77.30 in after-hours trading.See Also: Attention Biotech Investors: Mark Your Calendar For These January PDUFA DatesIllumina, Pacific Biosciences Terminate $1.2B Merger AgreementIllumina, Inc. (NASDAQ: ILMN) and
Pacific Biosciences of California (NASDAQ: PACB) said they have mutually agreed to terminate their $1.2 billion all-cash merger agreement announced Nov. 2018. The companies cited the lengthy regulatory process and continued uncertainty of the ultimate outcome as reasons for the snapping of the deal.Illumina said it would pay Pac Bio a termination fee of $98 million.Nuvasive Appoints New CFO, Reaffirms FY19 GuidanceNuvasive said it has appointed Matthew Harbaugh as EVP and CFO, effective immediately, following the incumbent Rajesh Asarpota transitioning from the company. The company also reaffirmed its full-year guidance.Chembio Expects FDA Approval For its HIV, Syphilis Screening Test In Q1'20Chembio Diagnostics Inc
(NASDAQ: CEMI) said it anticipates FDA approval for its DPP HIV-Syphilis System, which includes the DPP HIV-Syphilis test and DPP Micro Reader, during the first quarter of 2020. The company added its clinical study demonstrated that the system met the performance requirements established with the FDA.DPP HIV-Syphilis System is a single-use, 15-minute screening test for the simultaneous detection of antibodies to HIV types 1 and 2 and the bacteria that causes syphilis, Treponema pallidum.The stock rallied 19.30% to $5.44 in after-hours trading.Novan's Viral Skin Infection Treatment Fails In Late-Stage TrialNovan Inc
(NASDAQ: NOVN) released top-line efficacy results from the Phase 3 B-SIMPLE program that evaluated SB206 for the treatment of molluscum contagiosum, which showed that statistical significance was not achieved for the primary endpoint in either B-SIMPLE1 or B-SIMPLE2.However, the company said sensitivity analyses are supportive and consistent across both studies, supporting a path forward. The company now awaits 24-week safety data from the two trials.The stock plunged 72.67% to 85 cents in after-hours trading.DBV Appoints Ramzi Benamar as CFODBV announced the appointment of Ramzi Benamar as its CFO, effective Jan. 6, taking over the responsibility from Sebastien Robitaille, who was holding the role on an interim basis since Aug. 2019.OncoCyte Announces $7.6M Registered Common Stock OfferingOncoCyte Corp (NYSE: OCX) has entered into a definitive agreement with Pura Vida Investments and another institutional investor to purchase about $7.6 million of its common shares in a registered offering. In connection with the offering, the company said it will sell 3.524 million shares at $2.156 apiece. The offering is expected to close during the week of Jan. 6.Transenterix Appoints Brett Farabaugh as Interim CFOTransenterix Inc (NYSE: TRXC) said it has appointed Brett Farabaugh as interim CFO, effective Jan. 2, replacing Joe Slattery, who retired Dec. 31.The stock slipped 0.66% to $1.50 in after-hours trading.0See more from BenzingaThe Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In EuropeWeek Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextValley tech companies see limited coronavirus impact; analyst warns it could be comingAmerican City Business JournalsIn a week of losers, these Oregon stocks fared the worstAmerican City Business JournalsThe Dow Jones drops nearly 1,200 points as coronavirus fears batter stock marketsTechCrunchDow Plunges 1,200 Points As Stock Market Melts Down Again On Coronavirus FearsInvestor's Business Daily'It's a bloodbath': Stocks plummet even further as coronavirus chokes US economyThe IndependentRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoIBD's Investing Podcast: How To Make More Money In The Stock Market With Stock ChartsInvestor's Business DailyDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video